Scott C Neu1, Judy Pa1, Walter Kukull2, Duane Beekly2, Amanda Kuzma3, Prabhakaran Gangadharan3, Li-San Wang3, Klaus Romero4, Stephen P Arneric4, Alberto Redolfi5, Daniele Orlandi5, Giovanni B Frisoni5,6, Rhoda Au7,8,9, Sherral Devine10, Sanford Auerbach10, Ana Espinosa11, Mercè Boada11, Agustín Ruiz11, Sterling C Johnson12, Rebecca Koscik12, Jiun-Jie Wang13,14, Wen-Chuin Hsu15,16, Yao-Liang Chen17,18, Arthur W Toga1. 1. Laboratory of Neuro Imaging, Stevens Institute for Neuroimaging and Informatics, Keck School of Medicine, University of Southern California, Los Angeles. 2. National Alzheimer's Coordinating Center, University of Washington, Seattle. 3. Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia. 4. Coalition Against Major Disease, Critical Path Institute, Tucson, Arizona. 5. IRCCS Fatebenefratelli, The National Centre for Alzheimer's Disease, Brescia, Italy. 6. University Hospitals and University of Geneva, Geneva, Switzerland. 7. Department of Anatomy and Neurobiology, Boston University Schools of Medicine and Public Health, Boston, Massachusetts. 8. Department Neurology and Epidemiology, Boston University Schools of Medicine and Public Health, Boston, Massachusetts. 9. Framingham Heart Study, Boston University Schools of Medicine and Public Health, Boston, Massachusetts. 10. Department of Neurology, Framingham Heart Study, Boston University School of Medicine, Boston, Massachusetts. 11. Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain. 12. University of Wisconsin School of Medicine and Public Health, Madison. 13. Department of Medical Imaging and Radiological Sciences, Chang Gung University, Taoyuan City, Taiwan. 14. Neuroscience Research Center, Chang Gung Memorial Hospital at Linkou, Taoyuan City, Taiwan. 15. Department of Neurology, Chang Gung Memorial Hospital at Linkou, Taoyuan City, Taiwan. 16. Dementia Center, Chang Gung Memorial Hospital at Linkou, Taoyuan City, Taiwan. 17. Department of Medical Imaging and Intervention, Chang Gung Memorial Hospital at Linkou, Taoyuan City, Taiwan. 18. Department of Medical Imaging and Intervention, Keelung Branch, Chang Gung Memorial Hospital, Keelung City, Taiwan.
Abstract
Importance: It is unclear whether female carriers of the apolipoprotein E (APOE) ε4 allele are at greater risk of developing Alzheimer disease (AD) than men, and the sex-dependent association of mild cognitive impairment (MCI) and APOE has not been established. Objective: To determine how sex and APOE genotype affect the risks for developing MCI and AD. Data Sources: Twenty-seven independent research studies in the Global Alzheimer's Association Interactive Network with data on nearly 58 000 participants. Study Selection: Non-Hispanic white individuals with clinical diagnostic and APOE genotype data. Data Extraction and Synthesis: Homogeneous data sets were pooled in case-control analyses, and logistic regression models were used to compute risks. Main Outcomes and Measures: Age-adjusted odds ratios (ORs) and 95% confidence intervals for developing MCI and AD were calculated for men and women across APOE genotypes. Results: Participants were men and women between ages 55 and 85 years. Across data sets most participants were white, and for many participants, racial/ethnic information was either not collected or not known. Men (OR, 3.09; 95% CI, 2.79-3.42) and women (OR, 3.31; CI, 3.03-3.61) with the APOE ε3/ε4 genotype from ages 55 to 85 years did not show a difference in AD risk; however, women had an increased risk compared with men between the ages of 65 and 75 years (women, OR, 4.37; 95% CI, 3.82-5.00; men, OR, 3.14; 95% CI, 2.68-3.67; P = .002). Men with APOE ε3/ε4 had an increased risk of AD compared with men with APOE ε3/ε3. The APOE ε2/ε3 genotype conferred a protective effect on women (OR, 0.51; 95% CI, 0.43-0.61) decreasing their risk of AD more (P value = .01) than men (OR, 0.71; 95% CI, 0.60-0.85). There was no difference between men with APOE ε3/ε4 (OR, 1.55; 95% CI, 1.36-1.76) and women (OR, 1.60; 95% CI, 1.43-1.81) in their risk of developing MCI between the ages of 55 and 85 years, but women had an increased risk between 55 and 70 years (women, OR, 1.43; 95% CI, 1.19-1.73; men, OR, 1.07; 95% CI, 0.87-1.30; P = .05). There were no significant differences between men and women in their risks for converting from MCI to AD between the ages of 55 and 85 years. Individuals with APOE ε4/ε4 showed increased risks vs individuals with ε3/ε4, but no significant differences between men and women with ε4/ε4 were seen. Conclusions and Relevance: Contrary to long-standing views, men and women with the APOE ε3/ε4 genotype have nearly the same odds of developing AD from age 55 to 85 years, but women have an increased risk at younger ages.
Importance: It is unclear whether female carriers of the apolipoprotein E (APOE) ε4 allele are at greater risk of developing Alzheimer disease (AD) than men, and the sex-dependent association of mild cognitive impairment (MCI) and APOE has not been established. Objective: To determine how sex and APOE genotype affect the risks for developing MCI and AD. Data Sources: Twenty-seven independent research studies in the Global Alzheimer's Association Interactive Network with data on nearly 58 000 participants. Study Selection: Non-Hispanic white individuals with clinical diagnostic and APOE genotype data. Data Extraction and Synthesis: Homogeneous data sets were pooled in case-control analyses, and logistic regression models were used to compute risks. Main Outcomes and Measures: Age-adjusted odds ratios (ORs) and 95% confidence intervals for developing MCI and AD were calculated for men and women across APOE genotypes. Results:Participants were men and women between ages 55 and 85 years. Across data sets most participants were white, and for many participants, racial/ethnic information was either not collected or not known. Men (OR, 3.09; 95% CI, 2.79-3.42) and women (OR, 3.31; CI, 3.03-3.61) with the APOE ε3/ε4 genotype from ages 55 to 85 years did not show a difference in AD risk; however, women had an increased risk compared with men between the ages of 65 and 75 years (women, OR, 4.37; 95% CI, 3.82-5.00; men, OR, 3.14; 95% CI, 2.68-3.67; P = .002). Men with APOE ε3/ε4 had an increased risk of AD compared with men with APOE ε3/ε3. The APOE ε2/ε3 genotype conferred a protective effect on women (OR, 0.51; 95% CI, 0.43-0.61) decreasing their risk of AD more (P value = .01) than men (OR, 0.71; 95% CI, 0.60-0.85). There was no difference between men with APOE ε3/ε4 (OR, 1.55; 95% CI, 1.36-1.76) and women (OR, 1.60; 95% CI, 1.43-1.81) in their risk of developing MCI between the ages of 55 and 85 years, but women had an increased risk between 55 and 70 years (women, OR, 1.43; 95% CI, 1.19-1.73; men, OR, 1.07; 95% CI, 0.87-1.30; P = .05). There were no significant differences between men and women in their risks for converting from MCI to AD between the ages of 55 and 85 years. Individuals with APOE ε4/ε4 showed increased risks vs individuals with ε3/ε4, but no significant differences between men and women with ε4/ε4 were seen. Conclusions and Relevance: Contrary to long-standing views, men and women with the APOE ε3/ε4 genotype have nearly the same odds of developing AD from age 55 to 85 years, but women have an increased risk at younger ages.
Authors: May A Beydoun; Adel Boueiz; Marwan S Abougergi; Melissa H Kitner-Triolo; Hind A Beydoun; Susan M Resnick; Richard O'Brien; Alan B Zonderman Journal: Neurobiol Aging Date: 2010-07-08 Impact factor: 4.673
Authors: Jon Neville; Steve Kopko; Steve Broadbent; Enrique Avilés; Robert Stafford; Christine M Solinsky; Lisa J Bain; Martin Cisneroz; Klaus Romero; Diane Stephenson Journal: Alzheimers Dement Date: 2015-02-09 Impact factor: 21.566
Authors: D Tsuang; W Kukull; L Sheppard; R L Barnhart; E Peskind; S D Edland; G Schellenberg; M Raskind; E B Larson Journal: J Am Geriatr Soc Date: 1996-06 Impact factor: 5.562
Authors: Minerva M Carrasquillo; Fanggeng Zou; V Shane Pankratz; Samantha L Wilcox; Li Ma; Louise P Walker; Samuel G Younkin; Curtis S Younkin; Linda H Younkin; Gina D Bisceglio; Nilufer Ertekin-Taner; Julia E Crook; Dennis W Dickson; Ronald C Petersen; Neill R Graff-Radford; Steven G Younkin Journal: Nat Genet Date: 2009-01-11 Impact factor: 38.330
Authors: N T Lautenschlager; L A Cupples; V S Rao; S A Auerbach; R Becker; J Burke; H Chui; R Duara; E J Foley; S L Glatt; R C Green; R Jones; H Karlinsky; W A Kukull; A Kurz; E B Larson; K Martelli; A D Sadovnick; L Volicer; S C Waring; J H Growdon; L A Farrer Journal: Neurology Date: 1996-03 Impact factor: 9.910
Authors: L A Farrer; L A Cupples; J L Haines; B Hyman; W A Kukull; R Mayeux; R H Myers; M A Pericak-Vance; N Risch; C M van Duijn Journal: JAMA Date: 1997 Oct 22-29 Impact factor: 56.272
Authors: Lisa Vermunt; Sietske A M Sikkes; Ardo van den Hout; Ron Handels; Isabelle Bos; Wiesje M van der Flier; Silke Kern; Pierre-Jean Ousset; Paul Maruff; Ingmar Skoog; Frans R J Verhey; Yvonne Freund-Levi; Magda Tsolaki; Åsa K Wallin; Marcel Olde Rikkert; Hilkka Soininen; Luisa Spiru; Henrik Zetterberg; Kaj Blennow; Philip Scheltens; Graciela Muniz-Terrera; Pieter Jelle Visser Journal: Alzheimers Dement Date: 2019-06-01 Impact factor: 21.566
Authors: Donald M Lyall; Carlos Celis-Morales; Laura M Lyall; Christopher Graham; Nicholas Graham; Daniel F Mackay; Rona J Strawbridge; Joey Ward; Jason M R Gill; Naveed Sattar; Jonathan Cavanagh; Daniel J Smith; Jill P Pell Journal: Neurology Date: 2019-04-26 Impact factor: 9.910
Authors: Rachel F Buckley; Elizabeth C Mormino; Rebecca E Amariglio; Michael J Properzi; Jennifer S Rabin; Yen Ying Lim; Kathryn V Papp; Heidi I L Jacobs; Samantha Burnham; Bernard J Hanseeuw; Vincent Doré; Annette Dobson; Colin L Masters; Michael Waller; Christopher C Rowe; Paul Maruff; Michael C Donohue; Dorene M Rentz; Dylan Kirn; Trey Hedden; Jasmeer Chhatwal; Aaron P Schultz; Keith A Johnson; Victor L Villemagne; Reisa A Sperling Journal: Alzheimers Dement Date: 2018-05-24 Impact factor: 21.566
Authors: Michael E Belloy; Valerio Napolioni; Summer S Han; Yann Le Guen; Michael D Greicius Journal: JAMA Neurol Date: 2020-07-01 Impact factor: 18.302